Unknown

Dataset Information

0

Precision Vaccine Adjuvants for Older Adults: A Scoping Review.


ABSTRACT: Older adults, defined as those ≥60 years of age, are a growing population vulnerable to infections including severe acute respiratory syndrome coronavirus 2. Although immunization is a key to protecting this population, immunosenescence can impair responses to vaccines. Adjuvants can increase the immunogenicity of vaccine antigens but have not been systematically compared in older adults. We conducted a scoping review to assess the comparative effectiveness of adjuvants in aged populations. Adjuvants AS01, MF59, AS03, and CpG-oligodeoxynucleotide, included in licensed vaccines, are effective in older human adults. A growing menu of investigational adjuvants, such as Matrix-M and CpG plus alum, showed promising results in early phase clinical trials and preclinical studies. Most studies assessed only 1 or 2 adjuvants and no study has directly compared >3 adjuvants among older adults. Enhanced preclinical approaches enabling direct comparison of multiple adjuvants including human in vitro modeling and age-specific animal models may derisk and accelerate vaccine development for older adults.

SUBMITTER: Nanishi E 

PROVIDER: S-EPMC9376277 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Precision Vaccine Adjuvants for Older Adults: A Scoping Review.

Nanishi Etsuro E   Angelidou Asimenia A   Rotman Chloe C   Dowling David J DJ   Levy Ofer O   Ozonoff Al A  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20220801 Suppl 1


Older adults, defined as those ≥60 years of age, are a growing population vulnerable to infections including severe acute respiratory syndrome coronavirus 2. Although immunization is a key to protecting this population, immunosenescence can impair responses to vaccines. Adjuvants can increase the immunogenicity of vaccine antigens but have not been systematically compared in older adults. We conducted a scoping review to assess the comparative effectiveness of adjuvants in aged populations. Adju  ...[more]

Similar Datasets

| S-EPMC9773036 | biostudies-literature
| S-EPMC9807101 | biostudies-literature
| S-EPMC10655301 | biostudies-literature
| S-EPMC9024019 | biostudies-literature
| S-EPMC8218209 | biostudies-literature
| S-EPMC10267779 | biostudies-literature
| S-EPMC9892987 | biostudies-literature
| S-EPMC7888354 | biostudies-literature
| S-EPMC8289951 | biostudies-literature
| S-EPMC5084984 | biostudies-other